
ACP urges ADA-aligned funding, inclusive trials, and accessible care to reduce disability disparities for underserved patients.

ACP urges ADA-aligned funding, inclusive trials, and accessible care to reduce disability disparities for underserved patients.

Experts discuss the potential unintended consequences of less children getting immunized if the current trends continue.

Amputee mobility improves with orthopedic Osseointegration prosthesis with faster walking, fewer fractures, durability watched.

In this episode of our roundtable discussion, four experts talk about the changes to the CDC’s ACIP meetings.

A COSMOS trial analysis found daily multivitamin use modestly slowed epigenetic markers of biological aging in older adults over 2 years.

Survey shows GI stigma makes Americans dismiss symptoms, delaying diagnosis and driving costs—why primary care conversations matter.

Orthopaedic osseointegration gives amputees a direct-to-bone prosthesis, boosting comfort, distance, and quality of life beyond sockets.

Experts review recent updates to the US childhood immunization schedule, including RSV prevention, hepatitis B birth dose changes, and expanded shared clinical decision making.

A new study shows virtual physician apps replace about half of clinic visits for young adults, while the rest adds new, low-risk demand.

ACP pushes disability-inclusive training, streamlined accommodations, and accessible clinics to narrow health gaps for disabled patients.

Assess your knowledge of fiber targets, fruit and vegetable serving goals, and microbiome guidance in the 2025–2030 Dietary Guidelines.

Long-term stress links to higher postpartum blood pressure only after pregnancy complications, suggesting stress screening and management may help reduce future CVD risk.

Sputum flow cytometry identifies biologic targets (CD124/CD125) to personalize asthma and COPD treatment.
.jpg?w=350&fit=crop&auto=format)
Deucravacitinib (Sotyktu) is the first TYK2 inhibitor approved for the treatment of PsA.

Five trials presented at AAAAI 2026 highlight new therapies and prevention strategies for hereditary angioedema, atopic dermatitis, asthma, and chronic urticaria.
.jpg?w=350&fit=crop&auto=format)
Large study links DASH and other healthy diets
CROI 2026: Phase III data show once-daily Eslatravir/Ravin matches BFTAF in treatment‑naive HIV, achieving high viral suppression at 48 weeks.


Phase 3 FINE-ONE shows finerenone cuts protein in urine for type 1 diabetes CKD patients, with manageable safety, hinting at new kidney protection.

ATS: Replace race-based PFTs with race-neutral GLI Global equations to improve clinical equity and accuracy.